NCT01434316 2026-03-18
Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
13 trialsNCT04870788 2026-03-11
Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06470971 2026-01-20
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT01591356 2026-01-07
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT06438588 2025-12-12
Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial
Mayo Clinic
Phase NA Recruiting
NCT05038839 2025-11-20
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04989556 2025-10-14
Technology-Enhanced Palliative Care for Advanced Cancer Patients
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT06630351 2025-10-14
Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Advanced Cancer
Mayo Clinic
Phase NA Enrolling by invitation
NCT03537690 2025-08-12
FID-007 in Treating Participants With Advanced Solid Tumors
University of Southern California
Phase 1 Active not recruiting
NCT04171219 2025-05-16
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03253679 2023-10-17
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
National Cancer Institute (NCI)
Phase 2 Completed
NCT01827384 2023-09-29
MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations
National Cancer Institute (NCI)
Phase 2 Completed
NCT04552704 2023-08-02
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
University of California, Davis
Phase 1/2 Terminated